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Abstract  
In this review, we present an overview of some of the medicinally-relevant organometallic 
drugs that have been used in the past or that are currently in clinical trials as well as an example 
of compounds that are currently in the initial stage of drug development. Three main classes of 
organometallic complexes have been chosen for discussion: antimicrobial organoarsenicals, 
antimalarial and anticancer ferrocene-containing compounds and anticancer catalytic 
organometallic complexes. The purpose of this review is to provide readers with a focus on the 
significant progress that has been made for each of these respective fields of medicine. 
Introduction 
An organometallic complex is generally defined as a metal-containing compound that has at 
least one direct, covalent metal-carbon bond.1 The most prominent examples of this class of 
compounds are most probably the (half-)sandwich compounds and the transition metal 
carbenes, with ferrocene and the Grubbs catalysts being typical examples of these two classes 
of organometallic complexes. Such compounds have found tremendous applications in catalysis 
or biosensing but, as surprising as it can be for certain readers of this article, also in medicine.2–
7 At this stage of the review, it is important to highlight that the famous platinum(II) anticancer 
drugs cisplatin, oxaliplatin and carboplatin, the antiarthritic gold(I) auranofin or the MRI agents 
based on gadolinium(III) are not organometallic complexes since they do not have a metal-
carbon bond – they are defined as coordination complexes. 
In this review, we intend to give the readers an overview of the (potential) use of organometallic 
compounds in medicine. We have chosen a few examples, selected by scientific importance 
and personal affinity to the field of research, to explain the concepts used so far with such 
complexes. More specifically, we are discussing below three main classes of medicinally-
relevant organometallic complexes, namely 1) antimicrobial organoarsenicals, 2) antimalarial 
and anticancer ferrocene-containing compounds and 3) anticancer catalytic organometallic 
complexes. Importantly, the selected examples include compounds which were or are approved 
(organoarsenicals), that are currently in (pre-)clinical trials (antimalarial and anticancer 
ferrocene-containing compounds) or that are, for the moment, at an initial stage of drug 
development (anticancer catalytic organometallic complexes). We note that we are not 
discussing herein anticancer Ru(II)-arene complexes since this topic has been extensively 
reviewed.1,8–10 
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Organoarsenicals 
 
An important structure-activity relationship (SAR) study was performed by Paul Ehrlich and 
Alfred Bertheim, at the beginning of the 20th century, to find a safer alternative to aminophenyl 
arsenic acid, also known by its commercial name Atoxyl® (Figure 1), to treat the African 
sleeping sickness (African trypanosomiasis).11 Atoxyl®, discovered by the French biologist 
Pierre Jacques Antoine Béchamp, had to be given in high doses, over a prolonged period, for 
an effective treatment. However, this treatment was leading to a high risk of blindness due to 
optic nerve atrophy. Ehrlich and Bertheim therefore undertook an important SAR study to 
unveil compound No. 418, named Spirasyl® or arsenophenylglycine (Figure 1). This 
compound, despite having still some side-effects, was employed to treat African sleeping 
sickness, which had high mortality rates,11 as of 1907. 
A breakthrough in the fight against syphilis happened in 1905 when Fritz Schaudinn and Erich 
Hoffmann discovered that the Treponema pallidum spirochete was the causal agent of syphilis. 
One has to remember that the impact of this disease was comparable to that of AIDS today. 
Due to the similarity between spirochetes and trypanosomes, Hoffmann advised Ehrlich to 
employ his series of arsenic compounds to treat patients with syphilis. To do this, Ehrlich 
capitalized on the discovery of Sahachiro Hata, a Japanese student, who joined Ehrlich’s lab. 
The testing of arsenic compounds on Hata’s syphilis infection in rabbits led to the emergence 
of compound No. 606, namely arspheamine. This was marketed in 1910 by Hoechst under the 
name Salvarsan®, ‘the arsenic that saves life” (Figure 1).  Worthy of note, Salvarsan® was later 
found to be a mixture of three- and five-membered cyclic compounds by mass spectrometry in 
2005 (Figure 1).12  
The lack of water-solubility of Salvarsan led to the preparation of compound No. 914 or 
neoarsphenamine (Figure 1), which was marketed in 1914 under the name Neosalvarsan®. 
Interestingly, in 1930, it was discovered that oxophenarsine (marketed under the name 
Mapharsen®, Figure 1) was actually the active metabolite of arsphenamine, which is oxidized 
upon intravenous injection in patient. Mapharsen®, which is stable contrary to arsphenamine, 
which had to be kept in sealed vials under a nitrogen atmosphere, therefore became the drug 
used for the treatment of syphilis until penicillin came to the market in 1940. Surprisingly, 
Mapharsen® was one of the compounds tested by Ehrlich and Hata (compound No. 599) but 
was dismissed due to its presumably high toxicity.11 
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An arseno-bismuth complex, namely Bimarsen® (Figure 1), was employed for the treatment of 
neurosyphilis due its low toxicity, tonic effect and ease of administration, although relapses 
were more often encountered, particularly in the central nervous system, than with other 
organoarsenical complexes.2,13 Other arsenic-containing compounds such as Bemarsal®, 
Amibiarson®, Stovarsol®, Gynoplix® or Collusulfar® (Figure 1) were used to treat infections 
caused by Entamoeba histolytica (Amebiasis), Trichomonas Vaginalis as well as Vincent’s 
Angina, respectively, with a few of these complexes having been withdrawn from the market 
only in the 1990s.2,13 
These days, arsenic-containing compounds are still being used. As2O3 (Trisenox®), which is 
not an organometallic compound, is currently being employed for the treatment of patients with 
relapsed acute myeloid leukemia.2,14 Melasorprol (Arsobal®) is still used to treat African 
sleeping sickness. Although not completely clear, the target of organoarsenical drugs is 
anticipated to be mitochondrial proteins involved in regulating the production of reactive 
oxidative species (ROS). Those proteins are inhibited by the disulphide linkage of vicinal thiol 
groups. This leads to increased ROS production and to induction of apoptotic signalling 
pathways.15 We also note that the mode of action of the approved arsenic-containing drug, 
As2O3, was found to be through the promotion of degradation of an oncogenic protein that 
drives the growth of APL cells, PML-RARa (a fusion protein containing sequences from the 
PML zinc finger protein and retinoic acid receptor alpha).16 For the readers who would like 
more information on the subject of organo-arsenicals, we invite them to look at different 
reviews or book chapters.2,11,13,17 
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Figure 1. Structures of different arsenic-containing compounds used in medicine. 
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Ferrocene-containing Drug Candidates 
In the past few decades, there has been increasing interest in the preparation of drug candidates 
derived from iron, especially in the form of ferrocene. Ferrocene is a compact metallocene 
which possesses low toxicity and is stable in non-oxidising environments. Its ability for 
reversible redox reactions contribute towards its antiparasitic and antitumor activity. In this 
section, we will touch briefly the history of ferrocenyl analogues, focus on the exciting progress 
of Ferroquine as an antimalarial candidate, and discuss its repurposing as an anticancer and 
antihepatitis C candidate. The anticancer drug candidate ferrocifen family of compounds will 
also be discussed.  
Ferrocerone (Figure 2a) holds the distinction of being the first ferrocene derivative to have been 
approved for clinical use in 1971 in the former USSR.1 It was first prepared by the Russian 
scientist, Alexander Nikolaevich Nesmeyanov to treat iron deficiency anaemia in children.18 
The idea was that the lipophilicity of the ferrocene moiety would allow for more effective oral 
administration, as compared to simple Fe(II) salts such as Ferrum-lek®, an iron(III)-hydroxide 
polymaltose complex, and Ferrocal®, a combination treatment of ferrous citrate and calcium 
citrate. Although Ferrocerone is no longer available on the market, other ferrocenyl-derived 
drug candidates carry on the legacy with their success in other areas of disease.19  
A prime example is the leading drug candidate against malaria, Ferroquine (FQ, SSR97193, 
Figure 2a). Designed in 1994 in Lille by the Brocard group, FQ is the ferrocene analogue of 
chloroquine (CQ, Figure 2a), a first-line anti-malarial drug which has issues with resistance due 
to mass administration programs. Studies showed that FQ was equally active in vitro against 
both CQ-sensitive and resistant Plasmodum falciparum (more active than CQ against CQ-
resistant strain). This is due to several factors: (i) The ferrocene moiety is located inside the 
lateral chain, which is key for the antimalarial activity of FQ towards CQ-resistant parasites. 
(ii) FQ also forms a 1:1 stiochiometric complex with haematin, resulting in the inhibition of β-
hematin formation (IC50 0.8 µM, vs CQ IC50 1.9 µM). Haematin is a product from the digestion 
of host-cell haemoglobin.20 Haematin is toxic due to its oxidative properties (production of 
ROS), which can disrupt cell membranes. Parasites can inactivate hematin by converting it to 
β-hematin.21 (ii) Due to the presence of the ferrocene moiety, FQ is at least 100 times more 
lipophilic than CQ at cytosolic pH 7.4, which facilitates transport through the cytosol to the 
food vacuole (pH 5.2), a site within the parasite where FQ is concentrated. (iii) The presence 
of the redox-active ferrocene moiety allows for the production of DNA-damaging hydroxyl 
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radicals in situ from hydrogen peroxide via a Fenton-type reaction.22 The levels of reactive 
oxygen species are low enough to have little effect on the stability of FQ, but high enough to 
promote significant damage to the membranes of the parasite food vacuole before resistance 
mechanisms can kick in.22 (iv) Furthermore, FQ is able to bypass current resistant mechanisms 
since the postulated transporter linked to CQ-resistance is extremely specific for CQ. This 
explainsthe activity of FQ against CQ-resistant strains. No other ferrocene analogues had equal 
or better anti-malarial activity despite the structure-activity investigation on another 120 
ferrocenyl derivatives. After various validations of its specific pharmacology,23,24 FQ entered 
phase I clinical trials with Sanofi-Aventis in 2003 in Gabon, Senegal, Cambodia, Thailand and 
Madagascar.24 Initially, FQ was used in dual therapy with artesunate (ARS), a semi-synthetic 
analogue of artemisinin,25 the traditional Chinese anti-malarial drug discovered by Tu Youyou 
(2015 Nobel prize winner in Medicine). FQ/ARS dual therapy was continued in Phase II clinical 
trials, resulting in high cure rates.26 Other studies27 were conducted concurrently with 
monotherapy to measure the pharmacokinetics parameters of FQ. In order to limit the risk of 
resistance, FQ/ARS was switched to a single dose combination therapy of FQ/OZ439 
(artefenomel, a novel synthetic trioxolane).28 FQ allows for long duration of plasma exposure, 
with activity against P. falciparum CQ-resistant parasites, while artefenomel has quick action 
and is active against artemeisinin-resistant parasites. Phase IIb studies are currently on-going 
with planned completion date in 2019. 
Current antimalarials such as CQ and hydroxychloroquine (HCQ) have also been repurposed29 
as anti-cancer candidates currently in clinical trials, due to their ability to selectively target 
autophagic-lysosomal function in cancer in vitro and in vivo.30 FQ was reported to have potent 
anti-cancer activity. Further investigations by the Biot group showed that FQ was able to induce 
cancer cell death in vitro and impair prostate tumour growth in vivo.29 Similar to CQ’s mode of 
action, FQ is able to accumulate within lysosomes, and deacidify them. FQ downregulates Akt 
kinase which plays a role in cell proliferation, and hypoxia-inducible factor-1α (HIF-1α), 
allowing it to be very effective in starved and hypoxic conditions29 frequently observed in 
advanced cancers. FQ induces lysosomal membrane permeabilization, mitochondrial 
depolarization and caspase-independent cancer cell death. In fact, multiple ferrocene-
containing molecules has been previously reported to have anticancer activity, hence 
application of ferrocene derivatives in cancer therapy is an active area of research.  
On the topic of cancer therapy with metal-based drugs and drug candidates, besides the well-
known platinum and ruthenium complexes cisplatin, oxaliplatin, carboplatin, KP1039, and 
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NAMI-A, we must not forget to highlight ferrocifen, a ferrocenyl derivative of Tamoxifen 
(Figure 2a). Tamoxifen (Nolvadex®) is a form of oral chemotherapy used for the prevention 
and treatment of breast cancer for more than 40 years.31 Reviews3,32,33 have summarized the 
mechanisms of action of ferrocifens. The most important point is that the ferrocifens have a 
different mode of action to the platinum anticancer drugs, targeting proteins rather than DNA 
bases. For example, three ferrocenophane complexes (Fc-OH-Tam, Fc-diOH and DP1)34 show 
a significant antiproliferative effect on cancer cells, but act via different mechanisms.3 These 
antiproliferative effects appear to be associated with both the redox process of ferrocene, and 
the formation of the quinone methide (QM). QM is first formed from the phenoxy radical which 
itself is formed from the redox process involving two electrons and two protons (see mechanism 
in Fig. 2b). QMs are electrophilic Michael acceptors which reduce quickly upon reaction with 
nucleophiles like glutathione or nucleobases found in enzymes and DNA. This reduction is 
usually fatal for the cell.  
In vivo studies with Fc-diOH on rats with implanted tumors (9L cells from glioma) have shown 
that Fc-diOH formulation in lipid nanocapsules (1 mg/g or 6.5 mg/g Fc-diOH in rats quantities 
of 2.5 or 16.2 mg/kg for 30 days) led to almost complete elimination of implanted tumors.35 
This indicates that other targets remain to be found, and that there are applications and 
mechanistic pathways that have to be further defined.  
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Figure 2 a) Ferrocenyl-containing drugs/drug candidtes and their parent compounds. b) 
Mechanism for the formation of quinone methides 
Organometallic Compounds as Anticancer Catalytic Drug Candidates 
As mentioned in the introduction, organometallic complexes are notoriously famous for their 
effectiveness in catalysing a variety of reactions. Over the last years, some of such compounds, 
namely organometallic Ru(II), Ir(III) and Os(II) complexes, have also been shown to enable 
effective killing of cancer cells.36–43 This opened up the field of anticancer metallodrug 
candidates. This new strategy, based on the unique architectures and redox potentials of 
organometallic compounds, could allow the unveiling of safer metal-based anticancer drug 
candidates (since lower doses are required) with potentially new modes of actions and 
overcoming platinum resistance. However, the majority of catalysis does work in organic 
solution and not in aqueous media in the presence of excess of nucleophiles such as thiols, 
which can poison the catalyst. Contrary to metalloenzymes, in which metal ions responsible for 
the catalytic activity are protected within protein cavities, metal centres in small-molecule 
catalysts are quite exposed to solvent. It was therefore required to develop first biocompatible 
catalyst for living cells.44–51 We note here that the works with nanoparticles by Bradley and 
Unciti-Broceta are not discussed herein since these are not organometallic compounds.52–54 
In 2008, the group of Peter Sadler pioneered this field by demonstrating that Ru(II) arene 
complexes such as 1 (Scheme 1) containing an iodido ligand (X in Scheme 1) and a σ-donor/π-
acceptor phenylazopyridine ligand were stable in aqueous solution but highly cytotoxic to 
human ovarian A2780 and human lung A549 cancer cells. The observation that the compounds 
were stable in aqueous solution but were toxic was not fitting with the accepted hypothesis that 
the halogen ligand(s) of Ru(II) arene were first exchanged with water before the water 
molecules will be exchanged with the N7 of guanine or the sulphur atoms of cysteines of 
proteins or enzymes. The bioactivity of the Ru(II) complex 1 was then explained by its action 
as a catalyst in reactions with glutathione (GSH, Scheme 1), a strong reducing peptide present 
in cells at millimolar concentrations. GSH was found to be oxidized to glutathione disulphide 
(GSSG) in the presence of micromolar ruthenium concentrations, as presented in Scheme 1. 
Very importantly, since no H2 was detected during the reaction, Sadler and co-workers 
postulated that the azo N=N group was regenerated by concomitant hydrogenation of dissolved 
O2 to generate H2O2. This H2O2 would then be transformed by iodide (displaced from Ru by 
the initial substitution reaction with GSH) to O2, explaining the observed gas bubbles (O2).37 
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The generation of reactive oxygen species (ROS) was shown to be responsible for cell death. 
Indeed, the chloro counterparts of these complexes (i.e. the organometallic complexes with a 
Ru-Cl bond instead of a Ru-I) were found to be much less cytotoxic and to not produce any 
ROS in living cells.37 Worthy of note, cancer cells have a higher basal level of ROS than healthy 
cells and are therefore more vulnerable to the generation of ROS compared to normal cells.55  
 
 
Scheme 1 a) Proposed cycle by Sadler and co-workers for the catalytic oxidation of GSH to its 
corresponding disulfide GSSG by ruthenium(II) arene phenylazopyridine complexes. Initially 
X is iodide, which is displaced by GS− during the early stages. Released iodide can catalyze the 
decomposition of H2O2. Bound GSH at pH 7 has deprotonated thiol and carboxyl groups, and 
a protonated amino group. Scheme adapted from ref.37 b) Catalytic conversion of NAD+ into 
1,4-NADH mediated by formate with a Ru(II) catalyst. Scheme adapted from ref.40 ; c) Ir(III) 
organometallic catalyst inducing oxidative stress in cancer cells.38 d) Catalytic reduction of 
pyruvate to lactate in aqueous solution by an Os(II) organometallic complex using formate as 
a hydride source; e) Structures of an active chiral Os(II) complex 3.36 
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This study was then followed by the first observation of the catalytic reduction of coenzyme 
NAD+ to 1,4-NADH in human ovarian cancer cells in the presence of Noyori-type ruthenium(II) 
sulfonamido ethyleneamine complexes (2, Scheme 1) using low, non-toxic doses of formate as 
a hydride donor.40 A cytotoxic activity enhancement by up to 14 times in the presence of 
formate and, very importantly, an increase in selectivity towards cancer cells versus normal 
cells were observed, thanks to this modulation of the NAD+/1,4-NADH redox couple. The 
mechanism of cancer cell death was found to involve the generation of reductive stress and  not 
to involve apoptosis or perturbation of mitochondrial membrane potentials. These results were 
therefore contrasting with the study of the same authors on an organometallic iridium 
cyclopentadienyl anticancer catalyst, which were inducing oxidative stress38 (Scheme 1c for the 
structure of the Ir(III) complexes). Overall, these two studies clearly confirm the extraordinary 
ability of organometallic complexes to modulate the redox status of cancer cells.40 
 
Very recently, the Sadler group demonstrated that highly stable chiral 16-electron half-
sandwich organometallic Os(II) arene sulfonyl diamine complexes (3, Scheme 1) were able to 
achieve a highly enantioselective reduction of pyruvate, a key intermediate in metabolic 
pathways, to D-lactate and L-lactate, respectively, in the presence of non-toxic concentrations 
of sodium formate used as a hydride source in human cancer cells (Scheme 1)36. This work is 
of high interest since it is based on two key vulnerabilities in cancer cells, namely 1) the high 
need for glucose for cancer cells resulting in an increased lactate accumulation (i.e. Warburg 
effect).56 Overexpression in cancer cells of lactate dehydrogenase (LDH), which catalyses the 
interconversion of pyruvate and lactate,57 is associated to a high likelihood of metastases and a 
poor clinical prognosis.58,59 Therefore, by converting pyruvate into lactate using an artificial 
catalysts and hydride source, the ability of cancer cells to harness energy and essential 
metabolites, such as NAD+ is threatened; 2) due to their high metabolic demand to satisfy their 
rapid proliferation, cancer cells are under redox stress. However, cancer cells cannot recover 
from redox stress and avoid damage since, contrary to healthy proliferating cells, they do not 
have fully functional mitochondria.59 Interestingly, as expected taking into account the 
rationales of this study just described, the authors could demonstrate selectivity towards ovarian 
cancer cells versus non-cancerous fibroblasts (both ovarian and lung) of their catalytic system. 
Interestingly, the authors also investigated the use of formylmethionine as a hydride source 
since it can release formate when catabolised by the deformylase enzyme, an enzyme 
overexpressed in certain cancer cells.36 In their conclusions, the authors also discussed the 
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potential of such discoveries in terms of potential clinical translation. They envisaged a co-
administration of the catalyst and the reducing agent using nanoparticle encapsulation or 
polymeric micelles to solve the problem of the presence of three different chemicals (i.e. 
substrate, reducing agent and catalyst) to allow for the catalysis to proceed.36  
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Concluding remarks 
It is undeniable that organometallic compounds are gaining increasing progress and 
significance within the field of medicine. Our discussion has traversed across a varied range of 
studies, from the antimicrobial organoarsenicals prominently used throughout history, to the 
ferrocene-containing compounds which have been investigated for different diseases such as 
malaria or cancer. Last but not least, we also covered the anticancer catalytic organometallic 
complexes, which were represented by the Ru(II) arenes, the Noyori-type ruthenium(II) 
sulfonamido ethyleneamines and the Os(II) arene sulfonyl diamines.  
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